Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma

Active, not recruiting

• Conditions: Hodgkin Lymphoma

• Registration Number: NCT06761599
• Lead Sponsor: Superior University

Brief Summary

Pulmonary toxicity during Hodgkin lymphoma treatment is significant for a variety of reasons, ranging from clinical care to therapeutic innovation and patient outcomes.

Detailed Description

Understanding chemotherapy-induced pulmonary issues, particularly bleomycin-induced toxicity, might enhance treatment efficacy, side effects, and quality of life for Hodgkin lymphoma patients. For Hodgkin lymphoma chemotherapy patients with pulmonary difficulties, which result in significant patient morbidity and mortality, early detection, proactive surveillance, and rapid management are required. Identifying the prevalence, risk factors, and clinical signs of pulmonary toxicity helps clinicians stratify treatment.

Study Timeline

• Study Start: 2024-02-18
• Primary Completion: 2024-07-15
• Study First Submitted: 2024-12-19
• Status Verified: 2025-01
• Study First Submitted QC: 2025-01-05
• Last Update Submitted: 2025-01-05
• Study First Posted: 2025-01-07
• Last Update Posted: 2025-01-07
• Study Completion: 2025-03-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 214

Inclusion Criteria

• Patients diagnosed with Hodgkin lymphoma (HL) receiving treatment.
• Patients of all ages and both genders.
• Patients with histologically confirmed HL, as per the WHO 2016 classification.
• Patients who have undergone pulmonary function testing and assessment at specified time points during their treatment course.
• Patients with complete medical records documenting treatment regimens, including chemotherapy and radiotherapy details.

Exclusion Criteria

• Patients with a diagnosis of another malignancy.
• Patients with incomplete medical records or missing data on treatment regimens and pulmonary function assessments.
• Patients with a history of significant pulmonary comorbidities, such as chronic obstructive pulmonary disease (COPD), interstitial lung disease, or pulmonary fibrosis, before HL diagnosis.
• Patients who are unable to complete pulmonary function tests.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
high-resolution computed tomography	12 Months	An HRCT (high-resolution computed tomography) scan is a type of CT scan healthcare providers use to get detailed images of your lungs. Providers most commonly use it to diagnose and monitor interstitial lung diseases and conditions that affect your small airways and alveoli (air sacs).

Trial Locations

Locations (1)

Shaukat Khanum Memorial Cancer Hospital and Research Centre, 5-B, Sector A2, Phase 5, Hayatabad; 🇵🇰 Peshawar, Khyber Pakhtunkhwa, Pakistan